The legacy of general health and science information has long served as a foundation for public understanding of disease prevention and wellness. Within this broad context, discussions of environmental and pharmaceutical exposures have traditionally focused on communicable diseases and lifestyle factors, providing a baseline for risk communication. As scientific inquiry has matured, attention has increasingly turned to the nuanced relationships between specific therapeutic agents and long-term health outcomes. This evolution in health discourse now necessitates a more targeted examination of occupational and clinical exposures, particularly where emerging evidence suggests potential associations that warrant careful scrutiny. In the domain of mass production, where workers may encounter a range of chemical and biological agents, the transition from general health awareness to specific exposure concerns becomes critical. The focus shifts from broad preventive measures to the precise evaluation of risks linked to particular substances used in manufacturing processes. This pivot acknowledges that while general health principles remain valuable, the realities of industrial environments demand a refined approach—one that considers how specific exposures, such as those to certain pharmaceutical compounds, may intersect with occupational safety protocols.
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). This makes avelumab the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).
Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab and pembrolizumab, offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/).
However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a retrospective study conducted at three academic sites in Germany, clinical and molecular data of five patients with metastatic MCC who were refractory to avelumab and later treated with combined ipilimumab and nivolumab were collected and evaluated (https://pubmed.ncbi.nlm.nih.gov/33439294/). Three out of five patients responded to the combination therapy according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC further noted that despite advances in systemic therapy, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Regarding causation-related considerations, avelumab is approved for the treatment of metastatic MCC, meaning that its use is indicated in patients who already have the disease. The risk narrative here does not involve avelumab causing MCC; rather, avelumab is a therapeutic agent for MCC. The evidence does not suggest that avelumab induces or causes Merkel cell carcinoma. Instead, the risk concerns the adequacy of warnings regarding the potential for avelumab to be ineffective or to lead to disease progression in some patients. The timeline between exposure to avelumab and documented harm, such as disease progression or lack of response, is typically assessed during treatment. In the JAVELIN Merkel 200 trial, responses were observed in approximately one-third of patients, indicating that a majority did not achieve a confirmed objective response (https://pubmed.ncbi.nlm.nih.gov/29799096/). For patients who are refractory, the timeline to progression can vary, and alternative treatments like ipilimumab plus nivolumab may be considered (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/).
In summary, avelumab is an established treatment for metastatic MCC, with evidence supporting its efficacy in a subset of patients. The risk of non-response or progression is significant, affecting approximately 50% of patients. The evidence does not support a causal link between avelumab and the development of MCC; rather, it is used to treat the condition. Adequate warnings should inform patients and clinicians about the possibility of treatment failure and the need for alternative therapies in refractory cases.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
No, avelumab is a treatment for Merkel cell carcinoma, not a cause. It is an immune checkpoint inhibitor used to treat metastatic MCC. The evidence does not suggest that avelumab induces or causes the disease.
Approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors like avelumab do not respond or progress on therapy. This is a significant risk that should be discussed with patients.
For patients who are refractory to avelumab, combination therapy with ipilimumab and nivolumab has shown some efficacy. In a small study, three out of five patients responded to this combination.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Free and confidential. No obligation — an initial records screening only.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.